Loading...
Alvotech Q1 2025 Earnings Report
Alvotech reported strong financial results for the first quarter of 2025, driven by significant increases in total and product revenues, and a positive adjusted EBITDA.
Key Takeaways
Alvotech reported a substantial increase in total revenues to $132.8 million in Q1 2025, up 260% from the previous year, and achieved a positive adjusted EBITDA of $20.5 million, a significant improvement from a negative $38.4 million in 2023. The company also raised its full-year guidance for top-line revenue and adjusted EBITDA.
Total Revenues increased by 260% to $132.8 million in Q1 2025.
Product Revenues surged by 786% to $109.9 million in Q1 2025.
Adjusted EBITDA turned positive at $20.5 million in Q1 2025, compared to negative $38.4 million in 2023.
Full-year guidance for top-line revenue increased to $600-$700 million and adjusted EBITDA to $200-$280 million.
Alvotech
Alvotech
Alvotech Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comLicense and Other Revenue
CapyFin.comOther Income Revenue
CapyFin.com Forward Guidance
Alvotech has increased its full-year guidance for 2025, expecting top-line revenue between $600 million and $700 million and adjusted EBITDA between $200 million and $280 million, following the acquisition of a proposed biosimilar to Cimzia.
Positive Outlook
- Increased full-year guidance for top-line revenue to $600-$700 million.
- Increased full-year guidance for adjusted EBITDA to $200-$280 million.
- Positive cash flows from operating activities in Q1 2025.
- Expectation to be free cash-flow positive in 2025.
- Four new biosimilar launches remain key near-term priorities.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.